Inicio>>Signaling Pathways>> PROTAC>> PROTAC and Building Blocks>>CP5V

CP5V

Catalog No.GC62181

CP5V es un PROTAC conectado por ligandos para von Hippel-Lindau y CDK, que degrada especÍficamente Cdc20 uniendo Cdc20 al complejo VHL/VBC para la ubiquitinaciÓn seguida de degradaciÓn proteasomal. CP5V induce la inhibiciÓn mitÓtica y suprime la proliferaciÓn de células cancerosas.

Products are for research use only. Not for human use. We do not sell to patients.

CP5V Chemical Structure

Cas No.: 2509359-75-3

Tamaño Precio Disponibilidad Cantidad
5 mg
945,00 $
Disponible
10 mg
1.575,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

CP5V is a PROTAC, which specifically degrades Cdc20 by linking Cdc20 to the VHL/VBC complex for ubiquitination followed by proteasomal degradation. CP5V induces mitotic inhibition and suppresses cancer cell proliferation[1].

CP5V comprises a Cdc20 ligand and VHL binding moiety bridged by a PEG5 linker that induces Cdc20 degradation. CP5V induces degradation of Cdc20 leading to significant inhibition of breast cancer cell proliferation and resensitization of Taxol-resistant cell lines[1].CP5V profoundly degrades Cdc20 in both MCF7 and MDA-MB-231 cells with DC50 being approximately 1.6 μM[1].

[1]. Chi JJ, et al. A novel strategy to block mitotic progression for targeted therapy. EBioMedicine. 2019 Oct 25. pii: S2352-3964(19)30677-2.

Reseñas

Review for CP5V

Average Rating: 5 ★★★★★ (Based on Reviews and 6 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CP5V

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.